Advanced Therapeutics最新文献_第6页

From Spheroids to Bioprinting: A Literature Review on Biomanufacturing Strategies of 3D In Vitro Osteosarcoma Models 从球到生物打印：三维体外骨肉瘤模型生物制造策略文献综述

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-10 DOI: 10.1002/adtp.202400047

Margarida F. Domingues, João C. Silva, Paola Sanjuan-Alberte

{"title":"From Spheroids to Bioprinting: A Literature Review on Biomanufacturing Strategies of 3D In Vitro Osteosarcoma Models","authors":"Margarida F. Domingues, João C. Silva, Paola Sanjuan-Alberte","doi":"10.1002/adtp.202400047","DOIUrl":"https://doi.org/10.1002/adtp.202400047","url":null,"abstract":"Osteosarcoma (OS) is a rare primary malignant bone cancer affecting mainly young individuals. Treatment typically consists of chemotherapy and surgical tumor resection, which has undergone few improvements since the 1970s. This therapeutic approach encounters several limitations attributed to the tumor's inherent chemoresistance, marked heterogeneity and metastatic potential. Therefore, the development of in vitro platforms that closely mimic the OS pathophysiology is crucial to understand tumor progression and discover effective anticancer therapeutics. Contrary to 2D monolayer cultures and animal models, 3D in vitro platforms show promise in replicating the 3D tumor macrostructure, cell-cell and cell-extracellular matrix interactions. This review provides an overview of the biomanufacturing strategies employed in developing 3D in vitro OS models, highlighting their role in replicating different aspects of OS and improving OS anticancer research and drug screening. A variety of 3D in vitro models are explored, including both scaffold-free and scaffold-based models, encompassing cell spheroids, hydrogels, and innovative approaches like electrospun nanofibers, microfluidic devices and bioprinted constructs. By examining the distinctive features of each model type, this review offers insights into their potential transformative impact on the landscape of OS research and therapeutic innovation, addressing the challenges and future directions of 3D in vitro OS modeling.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 11","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Controlled Drug Release Systems for Cerebrovascular Diseases

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-08 DOI: 10.1002/adtp.202400239

Celia Martín-Morales, Sofia Caspani, Manuel Desco, Célia Tavares de Sousa, María Victoria Gómez-Gaviro

引用次数: 0

A Pilot Analysis of Capecitabine Plus PD-1 Antibody as Maintenance Therapy in Advanced or Metastatic Gastric Cancer and the Prognostic Factors 卡培他滨加 PD-1 抗体作为晚期或转移性胃癌维持疗法的试验分析及预后因素分析

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-04 DOI: 10.1002/adtp.202400177

Dong-Liang Chen, Yan Hu, Dong-Sheng Zhang, Feng-Hua Wang

{"title":"A Pilot Analysis of Capecitabine Plus PD-1 Antibody as Maintenance Therapy in Advanced or Metastatic Gastric Cancer and the Prognostic Factors","authors":"Dong-Liang Chen, Yan Hu, Dong-Sheng Zhang, Feng-Hua Wang","doi":"10.1002/adtp.202400177","DOIUrl":"https://doi.org/10.1002/adtp.202400177","url":null,"abstract":"Oxaliplatin-based chemotherapy combined with PD-1 antibody has become the standard treatment for advanced or metastatic gastric cancer. However, the neurotoxicity of oxaliplatin limits its long-term use. A total of 84 patients who received oxaliplatin-based chemotherapy plus PD-1 antibody are enrolled in this study, among which 44 patients are maintained with capecitabine plus PD-1 antibody, whereas the other 40 patients are maintained with capecitabine monotherapy. The primary endpoint is progression-free survival (PFS) and the secondary endpoint is overall-survival (OS). Subgroup analysis is performed based on expression of PD-L1 and CXCL12. The median PFS is significantly longer in capecitabine plus PD-1 antibody group (n = 44) than that in capecitabine monotherapy (n = 40) group. The median OS is significantly longer in capecitabine plus PD-1 antibody group than that in capecitabine monotherapy group. Subgroup analysis showed that patients with high expression of PD-L1 or low level of CXCL12 benefited more significantly from capecitabine plus PD-1 antibody maintenance. Maintenance therapy with capecitabine plus PD-1 antibody significantly prolongs the PFS and OS in patients without disease progression after first-line treatment. Patients with high expression of PD-L1 or low expression of CXCL12 benefit more significantly from maintenance therapy.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 11","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combinatory Immunotherapy for Glioblastoma Treatment 治疗胶质母细胞瘤的联合免疫疗法

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-02 DOI: 10.1002/adtp.202400217

Muhammad Ijaz, Ikram Hasan, Zhiru Jiang, Zia Ullah, Bilal Aslam, Mohsin Khurshid, Yansun Sun, Bing Guo

{"title":"Combinatory Immunotherapy for Glioblastoma Treatment","authors":"Muhammad Ijaz, Ikram Hasan, Zhiru Jiang, Zia Ullah, Bilal Aslam, Mohsin Khurshid, Yansun Sun, Bing Guo","doi":"10.1002/adtp.202400217","DOIUrl":"https://doi.org/10.1002/adtp.202400217","url":null,"abstract":"Despite advancements in the treatment of glioblastoma, it faces challenges due to tumor heterogeneity, the blood-brain barrier, recurrence, immune evasion, and conventional strategies, leading to low survival and a poor prognosis. Therefore, it is crucial to develop novel, useful treatment strategies for improving brain distribution to overcome blood-brain barriers (BBB) and help the treatment of glioblastoma. Conventional immunotherapy like checkpoint inhibitors, CAR-T cell therapy, monoclonal antibodies, cancer vaccines, and adoptive cell transfer often suffers from low therapeutic outcomes because the singular therapy generally has shortcomings, such as the cold immune microenvironment of brain tumors. In contrast, the emerging combinatory immunotherapy integrated with chemo-immunotherapy, photothermal-immunotherapy, and radio-immunotherapy has shown great promise to modulate tumoral immune microenvironment and boost treatment outcomes. This review discusses the immune microenvironment of GBM, its impact on immunological effects, current immunotherapy methods, and advanced studies. It also introduces combinational GBM immunotherapy with traditional cancer therapies like chemo-immunotherapy, surgery-immunotherapy, photothermal-immunotherapy, and radiotherapy-immunotherapy. In the future, it is anticipated that this article will provide beneficial information and a path for the strategy of innovative, efficient combination immunotherapy in the treatment of glioblastoma.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 11","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Wireless Light-Emitting Diode-Driven Functional Microneedle Devices for Skin Cancer Therapy 用于皮肤癌治疗的无线发光二极管驱动功能微针设备

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-09-27 DOI: 10.1002/adtp.202400233

Miranda Oungeun, Supason Wanichwecharungruang, Eijiro Miyako

{"title":"Wireless Light-Emitting Diode-Driven Functional Microneedle Devices for Skin Cancer Therapy","authors":"Miranda Oungeun, Supason Wanichwecharungruang, Eijiro Miyako","doi":"10.1002/adtp.202400233","DOIUrl":"https://doi.org/10.1002/adtp.202400233","url":null,"abstract":"Photodynamic therapy, a noninvasive cancer treatment strategy, is a promising remedy for malignant skin cancers. However, treatment of skin cancer with this method requires sufficient photosensitizer molecules to permeate into cancer cells before illumination for effective activation to induce potent reactive oxygen species for eliminating cancer cells. However, transdermal drug delivery using conventional photosensitizers faces major challenges due to skin barriers, diminishing the effectiveness of drug penetration and therapeutic efficacies. To overcome these limitations, biocompatible, physiologically dissolvable, and optically activatable functional microneedle devices are applied for effective percutaneous penetration of drug molecules into solid tumors in a murine model. The proposed wireless light-emitting diode light-driven functional microneedle device that effectively induces apoptosis of cancer cells and disruption of the tumor area and can enhance in vitro, ex vivo, and in vivo drug-delivery effectiveness for treating skin cancer. The design and strategy of the present functional microneedle devices can help shed light on future advanced cancer therapy.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 11","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400233","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hybrid Nanoparticles Dual-Loaded With Curcumin and Benzydamine Hydrochloride for the Treatment of Vulvovaginal Candidiasis: From Development to Biological Application In Vitro and In Vivo

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-09-27 DOI: 10.1002/adtp.202400342

Gabriela C. Carvalho, Maria Nolasco Viseu Domingues, Gabriel Davi Marena, Ermei Mäkilä, Jiachen Li, Gésinda Geertsema-Doornbusch, Cleverton Roberto de Andrade, Marc C. A. Stuart, Mohammad-Ali Shahbazi, Ione Corrêa, Brandon W. Peterson, Jarno Salonen, Helena F. Florindo, Taís Maria Bauab, Marlus Chorilli, Hélder A. Santos

{"title":"Hybrid Nanoparticles Dual-Loaded With Curcumin and Benzydamine Hydrochloride for the Treatment of Vulvovaginal Candidiasis: From Development to Biological Application In Vitro and In Vivo","authors":"Gabriela C. Carvalho, Maria Nolasco Viseu Domingues, Gabriel Davi Marena, Ermei Mäkilä, Jiachen Li, Gésinda Geertsema-Doornbusch, Cleverton Roberto de Andrade, Marc C. A. Stuart, Mohammad-Ali Shahbazi, Ione Corrêa, Brandon W. Peterson, Jarno Salonen, Helena F. Florindo, Taís Maria Bauab, Marlus Chorilli, Hélder A. Santos","doi":"10.1002/adtp.202400342","DOIUrl":"https://doi.org/10.1002/adtp.202400342","url":null,"abstract":"Vulvovaginal candidiasis represents a public health challenge due to its reports of high incidence and recurrence. These are caused by host-related factors like compromised immune system, or pathogen-related factors, such as resistance to antifungal agents, making this medical problem desirable to develop new therapeutic options. In this context, natural origin substances like curcumin, are increasingly treatment alternatives. However, some curcumin properties limit its therapeutic application, such as insolubility in aqueous solvents, which leads to low bioavailability. Nevertheless, nanotechnology association with drugs of plant origin proves to be a promising alternative to overcome the reported drawbacks. Despite being caused by a fungus, patients suffer significantly from the inflammation resulting from this disease, thus this study aimed to develop a hybrid carrier nanoformulation by microfluidics loaded with two drugs, benzydamine hydrochloride (an anti-inflammatory drug) and curcumin (an antifungal drug). Transmission electron cryomicroscopy combined with energy dispersive X-ray analysis confirmed that the nanoparticle is properly developed. Through in vitro biological studies, it is possible to observe that, in addition to being safe, the encapsulation of both drugs in the nanocarrier drastically reduced their cytotoxicity. Finally, although the final nanoformulation does not show in vitro activity, the in vivo study indicated therapeutic potential.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400342","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143119949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mucoadhesive Itraconazole Nanocrystals With Precise Control of Surface Charge Incorporated to Chitosan Films for Buccal Drug Delivery 精确控制壳聚糖薄膜表面电荷的粘液黏附性伊曲康唑纳米晶体用于口腔给药

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-09-25 DOI: 10.1002/adtp.202400209

Chunyang Zhang, Lucia Lopez-Vidal, Jiawen Wang, Achmad Himawan, Ryan F. Donnelly, Alejandro J. Paredes

{"title":"Mucoadhesive Itraconazole Nanocrystals With Precise Control of Surface Charge Incorporated to Chitosan Films for Buccal Drug Delivery","authors":"Chunyang Zhang, Lucia Lopez-Vidal, Jiawen Wang, Achmad Himawan, Ryan F. Donnelly, Alejandro J. Paredes","doi":"10.1002/adtp.202400209","DOIUrl":"https://doi.org/10.1002/adtp.202400209","url":null,"abstract":"Drug delivery to mucosal tissues presents considerable challenges related to the complex nature of the mucus layer protecting such tissues. This aggravates when delivering hydrophobic drugs, often requiring incorporation of drugs to nanoparticles and use of mucoadhesive systems. This paper aimed to develop an antifungal chitosan (CHI)-based film loading itraconazole (ITZ) nanocrystals (NCs) with precisely controlled surface charge for enhanced mucoadhesion. Cationic and anionic ITZ NCs are prepared using wet media milling with mean particle sizes and zeta potentials of 226.9 ± 1.4 nm and 234.0 ± 2.90 nm, and +15.4 ± 2.8 mV and −16.2 ± 1.3 mV, for the cationic and anionic NCs, respectively. Cationic ITZ-NCs exhibits a higher affinity to mucin particles. NCs-loaded films showed stronger mechanical properties and adhesiveness compared with ITZ powder-loaded films. Physicochemical analysis reveals that crystalline properties of the ITZ are preserved, with no drug-excipients interaction. A significantly higher amount of ITZ mucosal deposition is obtained from films containing NCs (1360.23 ± 718.73 µg cm−2) compared with that from films containing ITZ powder (58.83 ± 37.45 µg cm−2). This work demonstrates the feasibility of tailoring the NCs surface, with the resultant systems showing potential for the management of fungal infections in mucosal tissues.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 11","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400209","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon 用宿主引导疗法（HDTs）治疗传染病，实现最佳健康状态--新视野

IF 4.6 4区医学

Advanced Therapeutics Pub Date : 2024-09-18 DOI: 10.1002/adtp.202400169

Amol D. Gholap, Pankaj R. Khuspe, Sagar R. Pardeshi, Md Jasim Uddin, Ushasi Das, Navnath T. Hatvate, Satish Rojekar, Prabhanjan Giram, Mohammad Khalid, Yahya E. Choonara, Md. Faiyazuddin

{"title":"Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon","authors":"Amol D. Gholap, Pankaj R. Khuspe, Sagar R. Pardeshi, Md Jasim Uddin, Ushasi Das, Navnath T. Hatvate, Satish Rojekar, Prabhanjan Giram, Mohammad Khalid, Yahya E. Choonara, Md. Faiyazuddin","doi":"10.1002/adtp.202400169","DOIUrl":"https://doi.org/10.1002/adtp.202400169","url":null,"abstract":"Host‐directed therapies (HDTs) have emerged as a promising strategy to combat viral infections by modifying host factors and immune responses to restrict viral replication and improve patient outcomes. This review summarizes the latest advances and future potential of HDTs in antiviral therapy. With developments in genomics and proteomics, new host targets essential for viral replication have been identified. Gene‐editing tools, such as CRISPR‐Cas9, enable precise manipulation of host genes linked to viral processes, paving the way for innovative HDTs. Emerging approaches, including RNA interference and viral interference, further demonstrate the potential to specifically modify host factors to inhibit viral replication. Additionally, probiotics are being explored for their capacity to enhance immune responses and modulate gut microbiota, offering a natural and safe method for boosting antiviral defenses. Despite these advancements, significant challenges remain, particularly in deciphering complex host–virus interactions and ensuring the safety and efficacy of these therapies. Continued research and clinical evaluation are essential to realize the full potential of HDTs. This review provides a comprehensive overview of current HDT strategies, emphasizing their promise in shaping future antiviral interventions.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"20 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142264863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Ru(II) Polypyridyl Complex Bearing Bathocuproine Ligand is a Potent Chemotherapeutic Agent Against Chemically Induced Skin Cancer Model 含有巴索库络因配体的 Ru(II) 多吡啶络合物是一种针对化学诱导皮肤癌模型的强效化疗药物

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-09-13 DOI: 10.1002/adtp.202400313

Maria George Elias, Stephanie Mehanna, Selim Nasser, Costantine F. Daher, Rony S. Khnayzer

{"title":"A Ru(II) Polypyridyl Complex Bearing Bathocuproine Ligand is a Potent Chemotherapeutic Agent Against Chemically Induced Skin Cancer Model","authors":"Maria George Elias, Stephanie Mehanna, Selim Nasser, Costantine F. Daher, Rony S. Khnayzer","doi":"10.1002/adtp.202400313","DOIUrl":"10.1002/adtp.202400313","url":null,"abstract":"Ruthenium-based compounds have emerged as prospective chemotherapeutic candidates with various mechanisms of action and minimal associated side effects compared to conventional metal-based chemotherapeutics. The present study explores the chemotherapeutic potential of [Ru(bpy)2BC]Cl2 (where bpy = 2,2′-bipyridine and BC = bathocuproine) or RuBC on a 7,12-dimethylbenz[a]anthracene/12-o-tetradecanoylphorbol-13-acetate (DMBA/TPA) murine skin carcinogenesis model. RuBC is well tolerated up to 2.5 mg kg−1; no changes in body weight, behavior or serum biochemistry are observed. Following IP injections, the bioavailability of the complex is high in the plasma, which favors its accumulation in the organs. Efficacy studies demonstrated that RuBC has a significant anticancer activity by week 7 of treatment and a decrease in tumor size is observed by week 6 in all tested groups. Based on western blot analyses, apoptosis through the intrinsic pathway is suggested as the main mechanism of cell death. A downregulation of the MAPK pathway is also observed. The results indicate that RuBC is a multi-mechanistic chemotherapeutic drug that has promising anticancer effects with significant potential for further investigation.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 12","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142264865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-Administration Self-Boosting Microneedle Patch for the Treatment of Obesity (Adv. Therap. 9/2024) 用于治疗肥胖症的单次给药自增效微针贴片（Adv. Therap.）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-09-11 DOI: 10.1002/adtp.202470019

Parbeen Singh, Tra Vinikoor, Nidhi Sharma, Nicole Nelson, Somasundaram Prasadh, Ralph Oiknine, Thanh Duc Nguyen

引用次数: 0